- Top-line results from AstraZeneca's (AZN +0.1%) Phase 3 clinical trial, ARCTIC, assessing durvalumab (MEDI4736) in patients with advanced/metastatic non-small cell lung cancer (NSCLC) are now expected in mid-November instead of late Q2. A spokesperson says the delay is due to the number of observed clinical events not yet reaching the protocol target.
-
ARCTIC is evaluating durvalumab as monotherapy or in combination with tremelimumab in NSCLC patients who have received at least two prior lines of platinum-based chemo.
- Durvalumab is a PD-L1 inhibitor and tremelimumab is CTLA-4 inhibitor. Almost three months ago, the company terminated late-stage development of the combo in metastatic pancreatic ductal carcinoma.
- Previously: AstraZeneca bails on late-stage cancer combo in pancreatic cancer (Feb. 3)